journal
https://read.qxmd.com/read/38529411/novel-molecular-targets-in-endometrial-cancer-mechanisms-and-perspectives-for-therapy
#1
REVIEW
Pamela Soberanis Pina, Stephanie Lheureux
Endometrial cancer (EC) has a high epidemiological impact with incidence and mortality rising worldwide. In recent years, the integration of the pathologic and molecular classification has provided relevant information to understand the heterogeneity in the biology of EC, which led to the evolution in the management of patients. Currently, therapeutic breakthroughs have been made in advanced EC to improve oncologic outcomes, with efforts to include patient reported outcomes. Precision and personalized medicine are under way in EC exploring different combination approaches to target cross-talk pathways, cancer cell microenvironment, and metabolic vulnerabilities and improve drug delivery...
2024: Biologics: Targets & Therapy
https://read.qxmd.com/read/38318098/mdmx-in-cancer-a-partner-of-p53-and-a-p53-independent-effector
#2
REVIEW
Wu Lin, Yuxiang Yan, Qingling Huang, Dali Zheng
The p53 tumor suppressor protein plays an important role in physiological and pathological processes. MDM2 and its homolog MDMX are the most important negative regulators of p53. Many studies have shown that MDMX promotes the growth of cancer cells by influencing the regulation of the downstream target gene of tumor suppressor p53. Studies have found that inhibiting the MDMX-p53 interaction can effectively restore the tumor suppressor activity of p53. MDMX has growth-promoting activities without p53 or in the presence of mutant p53...
2024: Biologics: Targets & Therapy
https://read.qxmd.com/read/38299120/advances-with-platelet-rich-plasma-for-bone-healing
#3
REVIEW
Blake M Bacevich, Richard David James Smith, Alec M Reihl, Augustus D Mazzocca, Ian D Hutchinson
Despite significant advances in the understanding and delivery of osteosynthesis, fracture non-union remains a challenging clinical problem in orthopaedic surgery. To bridge the gap, basic science characterization of fracture healing provides a platform to identify and target biological strategies to enhance fracture healing. Of immense interest, Platelet-rich plasma (PRP) is a point of care orthobiologic that has been extensively studied in bone and soft tissue healing given its relative ease of translation from the benchtop to the clinic...
2024: Biologics: Targets & Therapy
https://read.qxmd.com/read/38260716/recent-advancements-in-reducing-the-off-target-effect-of-crispr-cas9-genome-editing
#4
REVIEW
Misganaw Asmamaw Mengstie, Muluken Teshome Azezew, Tadesse Asmamaw Dejenie, Assefa Agegnehu Teshome, Fitalew Tadele Admasu, Awgichew Behaile Teklemariam, Anemut Tilahun Mulu, Melaku Mekonnen Agidew, Dagnew Getnet Adugna, Habtamu Geremew, Endeshaw Chekol Abebe
The CRISPR-Cas (Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)) and the associated protein (Cas9) system, a young but well-studied genome-editing tool, holds plausible solutions to a wide range of genetic disorders. The single-guide RNA (sgRNA) with a 20-base user-defined spacer sequence and the Cas9 endonuclease form the core of the CRISPR-Cas9 system. This sgRNA can direct the Cas9 nuclease to any genomic region that includes a protospacer adjacent motif (PAM) just downstream and matches the spacer sequence...
2024: Biologics: Targets & Therapy
https://read.qxmd.com/read/38250216/effect-of-n-acetylcysteine-on-cisplatin-toxicity-a-review-of-the-literature
#5
REVIEW
Angeles Citlali Zavala-Valencia, Liliana Velasco-Hidalgo, Armando Martínez-Avalos, Manuel Castillejos-López, Luz-María Torres-Espíndola
N-acetylcysteine (NAC) is a membrane-permeable cysteine precursor capable of enhancing the intracellular cysteine pool, enhancing cellular glutathione (GSH) synthesis, and thus potentiating the endogenous antioxidant mechanism. Late administration of NAC after cisplatin has been shown in different in vivo studies to reduce the side effects caused by various toxicities at different levels without affecting the antitumor efficacy of platinum, improving total and enzymatic antioxidant capacity and decreasing oxidative stress markers...
2024: Biologics: Targets & Therapy
https://read.qxmd.com/read/38235068/successful-response-to-golimumab-in-a-case-of-relapsing-polychondritis-overlapping-with-ulcerative-colitis
#6
Shu Kojima, Satohiro Matsumoto, Yudai Koito, Takaya Miura, Masanari Sekine, Takeshi Uehara, Takeharu Asano, Yasuhiro Yamaguchi, Hirosato Mashima
A 51-year-old Japanese man was diagnosed with left-sided ulcerative colitis (UC) at age 41. He was treated with mesalazine and azathioprine and maintained remission. At age 51, the patient developed bloody stools, abdominal pain, scleritis, arthritis, cough, bloody sputum, and pericardial effusion. Considering that pericardial effusion is an atypical extraintestinal complication of UC, and the patient met the diagnostic criteria for relapsing polychondritis (RP), a diagnosis of RP complicating a relapse of UC was made...
2024: Biologics: Targets & Therapy
https://read.qxmd.com/read/38145108/hypoxia-inducible-factor-1%C3%AE-through-ros-nlrp3-pathway-regulates-the-mechanism-of-acute-ischemic-stroke-microglia-scorching-mechanism
#7
JOURNAL ARTICLE
Xin Ma, Junxia Jiao, Mayila Aierken, Hong Sun, Li Chen
PURPOSE: In vitro experiments explored how the hypoxia-induced factor-1α (HIF-1α) regulates the regulation of pyroptosis in microglial cells (BV 2) in acute ischemic stroke through ROS/NLRP3 pathway. METHODS: The microglia acute phase oxygen-glucose deprivation/reoxygenation (OGD/R) was established, CCK-8 was applied to determine the optimal timing of intervention modeling. HIF-1α was overexpressed with stabilizer GF-4592 and HIF-1α small molecule interfering RNA (HIF-1α-siRNA), which was divided into group A (blank group), group B (OGD/R model group), group C (model+FG-4592 intervention group), group D (model+siRNA negative control group) and group E (model+HIF-1α-siRNA group)...
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/38115870/the-effect-of-two-years-of-secukinumab-treatment-on-bone-metabolism-in-patients-with-radiographic-axial-spondyloarthritis-results-from-daily-clinical-practice
#8
JOURNAL ARTICLE
Mark Siderius, Stan C Kieskamp, Freke Wink, Frans G M Kroese, Suzanne Arends, Anneke Spoorenberg
BACKGROUND: Our objective was to explore bone-related outcome and bone turnover markers (BTM) during 2 years of secukinumab treatment in patients with radiographic axial spondyloarthritis (r-axSpA) in daily clinical practice. METHODS: Included were consecutive r-axSpA outpatients from the Groningen Leeuwarden axSpA (GLAS) cohort treated with secukinumab for 2 years. At baseline and 2 years, spinal radiographic damage was assessed using the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS; 0-72), cervical facet joint involvement according the "de Vlam" scoring method (0-15) and radiographic vertebral fractures (VF) using the "Genant" method (grade 0-3)...
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/38059132/tocilizumab-vs-methotrexate-in-a-cohort-of-patients-affected-by-active-gca-a-comparative-clinical-and-ultrasonographic-study
#9
JOURNAL ARTICLE
Silvia Grazzini, Edoardo Conticini, Paolo Falsetti, Miriana D'Alessandro, Jurgen Sota, Riccardo Terribili, Caterina Baldi, Claudia Fabiani, Elena Bargagli, Luca Cantarini, Bruno Frediani
INTRODUCTION: No head-to-head study has assessed the superiority of tocilizumab versus methotrexate in giant cell arteritis (GCA), and few studies have demonstrated its effectiveness in terms of ultrasonographic findings, but without a control group. The primary endpoint was to assess whether tocilizumab was superior to methotrexate in inducing normalization of US findings, whereas the secondary endpoint was to assess the effectiveness of precocious withdrawal of glucocorticoids. METHODS: We prospectively enrolled all the patients with active GCA at our clinic...
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/37854341/serum-linc00152-and-uca1-in-hcv-induced-hepatocellular-carcinoma-clinical-significance-and-prognostic-value
#10
JOURNAL ARTICLE
Somaia Shehab-Eldeen, Abdallah Essa, Eman Salah Arafat, Asmaa Shaaban Sleem, Amal Abdelrasoul Alhosary, Ehab Darwish, Ali Essa, Omar Ahmed Al-Omair, Emad Ali Al-Khoufi, Abdulrhman Khaled Al Abdulqader, Ali Nada
BACKGROUND: Despite significant advancements in the molecular characterization of hepatocellular carcinoma (HCC), no oncogene addiction has been discovered. Long noncoding RNAs (lncRNAs) have a lot of promise as cancer biomarkers. LINC00152 and UCA1 have shown potential as diagnostic, prognostic, and therapeutic targets for human cancers. AIM: To investigate the diagnostic and prognostic potential of serum LINC00152 and UCA1 in hepatocellular carcinoma (HCC). METHODS: The expression levels of LINC00152 and UCA1 in blood samples from 120 patients (60 with HCC, 60 with liver cirrhosis) and 40 healthy subjects were assessed using real-time qRT-PCR...
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/37814674/treatment-persistence-of-apremilast-among-patients-with-psoriatic-arthritis
#11
JOURNAL ARTICLE
Amir Haddad, Nili Stein, Idit Lavi, Lisa Shynkar, Irina Bergman, Ilan Feldhamer, Arnon Dov Cohen, Walid Saliba, Devy Zisman
INTRODUCTION: Persistence in drug therapy reflects treatment effectiveness and tolerability. We aim to estimate the persistence of apremilast prescribed to patients with psoriatic arthritis (PsA) and to identify characteristics associated with treatment discontinuation in a real-world setting. METHODS: Patients with PsA treated with apremilast from January 2016 were identified from a large health database and followed until medication stop date (using 3-months grace period), death or the end of observation period (June 2021)...
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/37767463/molecular-biology-mechanisms-and-emerging-therapeutics-of-triple-negative-breast-cancer
#12
REVIEW
Zhiying Zhang, Rui Zhang, Donghai Li
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that is conventionally characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2), accounting for approximately 15-20% of all breast cancers. Compared to other molecular phenotypes, TNBC is typically associated with high malignancy and poor prognosis. Cytotoxic agents have been the mainstay of treatment for the past few decades due to the lack of definitive targets and limited therapeutic interventions...
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/37223116/effectiveness-of-rcts-pooling-evidence-on-mesenchymal-stem-cell-msc-therapeutic-applications-during-covid-19-epidemic-a-systematic-review
#13
REVIEW
Usha Rani Kandula, Addisu Dabi Wake
BACKGROUND: Global pandemic identified as coronavirus disease 2019 (COVID-19) has resulted in a variety of clinical symptoms, from asymptomatic carriers to those with severe acute respiratory distress syndrome (SARS) and moderate upper respiratory tract symptoms (URTS). This systematic review aimed to determine effectiveness of stem cell (SC) applications among COVID-19 patients. METHODS: Multiple databases of PubMed, EMBASE, Science Direct, Google Scholar, Scopus, Web of Science, and Cochrane Library were used...
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/37213261/new-uracil-analog-with-exocyclic-methylidene-group-can-reverse-resistance-to-taxol-in-mcf-7-cancer-cells
#14
JOURNAL ARTICLE
Angelika Długosz-Pokorska, Renata Perlikowska, Tomasz Janecki, Anna Janecka
INTRODUCTION: Taxol (Tx), a microtubule-stabilizing drug, has been widely used as a chemotherapeutic in several types of cancer. However, the development of resistance limited its application. One of the strategies used to prevent the emergence of drug resistance is combination treatment, involving at least two drugs. The aim of the current study was to assess if a new uracil analog, 3- p -bromophenyl-1-ethyl-5-methylidenedihydrouracil (U-359) can prevent the development of Tx resistance in breast cancer cells...
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/37163178/treating-alpelisib-induced-hyperinsulinemia-in-patients-with-advanced-breast-cancer-a-real-life-experience
#15
Ruth Percik, Cecilie Oedegaard Smith, Anca Leibovici, Ayelet Shai
PIK3CA activating mutations are found in 40% of advanced breast cancer and are associated with worse prognosis. PI3K blockage is associated with insulin resistance, leading to hyperglycemia and hyperinsulinemia. Alpelisib is the first PI3K inhibitor used in cancer treatment. Laboratory evidence indicated that alpelisib-induced hyperinsulinemia offsets the drug's efficacy, but insulin levels were not tested in the clinical trials that evaluated alpelisib for breast cancer. Hyperglycemia could also interfere with anti-tumor effects of PI3K inhibitors by inducing Immune tolerance and altered mitochondrial metabolism...
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/37101561/hypereosinophilic-dermatitis-successful-treatment-with-dupilumab
#16
Chenyu Wu, Jianzhong Zhang, Yan Zhao
Hypereosinophilic dermatitis (HED) is a subtype of hypereosinophilic syndrome. HED is characterized by eosinophilic granulocytes increased in peripheral blood and bone marrow and infiltrated in skin. The clinical manifestations of HED are diffussed by erythema, papule and maculopapule with severe itching. The etiology of HED is unknown. At present, in addition to HED with FIP1L1-PDGFRA fusion gene positive, whose treatment is tyrosine kinase inhibitor, other types of HED first-line treatment are oral glucocorticoids, supplemented by antihistamines and immunosuppressants...
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/36969332/why-and-how-should-ethiopia-establish-a-stem-cell-transplant-service-a-review-article
#17
REVIEW
Sintayehu Mekonnen, Hawi Farris
Ethiopia is attempting to reduce cancer-related morbidity and mortality through a strategic national cancer control plan but according to Globocan 2020, hematologic malignancies particularly leukemia and non-Hodgkin's lymphoma rank among the top five leading causes of new cancer incidence and cause of death among all age groups in both sexes. Hematopoietic stem-cell transplantation (HSCT) is an advanced treatment modality that makes the only effective treatment for cancer and non-cancer-related hematologic diseases unresponsive to conventional therapy...
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/36969331/critical-response-does-the-mutation-of-cancer-driver-genes-idh1-2-and-cd204-influence-cancer-metabolism-and-tumor-associated-macrophage-recruitment-in-tumor-microenvironment-letter
#18
JOURNAL ARTICLE
Novaria Sari Dewi Panjaitan, Sarwo Handayani, Rita Marleta Dewi
No abstract text is available yet for this article.
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/36969330/elevated-serum-vinculin-in-patients-with-hbv-hcv-associated-liver-cirrhosis-and-hepatocellular-carcinoma-a-pilot-study
#19
JOURNAL ARTICLE
Abdallah Essa, Enas Said Essa, Sara Mahmoud El-Deeb, Hossam Eldin Mostafa Seleem, Muthana Al Sahlawi, Omar Ahmed Al-Omair, Somaia Shehab-Eldeen
BACKGROUND: The stiffness of the extracellular matrix (ECM) controls many cellular processes, such as migration and differentiation. Cells detect stiffness through adhesion structures termed focal adhesions (FAs). Vinculin, an actin-binding FA protein, plays a pivotal role in FA-mediated mechanotransduction. AIM: This study aimed to explore the role of vinculin in the development of HBV/HCV-induced hepatocellular carcinoma (HCC). METHODS: Vinculin levels in a total number of 100 serum samples from patients with HBV/HCV-induced liver cirrhosis and HCC, as well as healthy controls, were analyzed using an enzyme-linked immunosorbent assay (ELISA)...
2023: Biologics: Targets & Therapy
https://read.qxmd.com/read/36969329/demonstration-of-safety-in-wild-type-mice-of-npfoxf1-a-novel-nanoparticle-based-gene-therapy-for-alveolar-capillary-dysplasia-with-misaligned-pulmonary-veins
#20
JOURNAL ARTICLE
Fatemeh Kohram, Zicheng Deng, Yufang Zhang, Abid A Al Reza, Enhong Li, Olena A Kolesnichenko, Samriddhi Shukla, Vladimir Ustiyan, Jose Gomez-Arroyo, Anusha Acharya, Donglu Shi, Vladimir V Kalinichenko, Alan P Kenny
INTRODUCTION: Alveolar Capillary Dysplasia with Misaligned Pulmonary Veins (ACDMPV) is a fatal congenital disease resulting from a pulmonary vascular endothelial deficiency of FOXF1, producing abnormal morphogenesis of alveolar capillaries, malpositioned pulmonary veins and disordered development of lung lobes. Affected neonates suffer from cyanosis, severe breathing insufficiency, pulmonary hypertension, and death typically within days to weeks after birth. Currently, no treatment exists for ACDMPV, although recent murine research in the Kalinichenko lab demonstrates nanoparticle delivery improves survival and reconstitutes normal alveolar-capillary architecture...
2023: Biologics: Targets & Therapy
journal
journal
41818
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.